Kornimate/medical-research-clean huggingface dataset:
combining aerobic exercise and virtual reality for cognitive-motor rehabilitation in pd

Conditions: Parkinson's Disease

Summary: this project will provide preliminary data on the feasibility and effects of exercise and vr on motor behavior and neuroplasticity in pd. results from this work will provide insight into whether combination interventions utilizing ae and vr have parallel effects on cognition, gait, and neuroplasticity in pd.

in this pilot proof-of-concept study, the study team will recruit 25 individuals with parkinson's disease who will perform aerobic exercise (ae) followed by virtual reality (vr). the study team will measure the effects of the intervention on dual task performance, clinical measures of gait, cognition, tms measures and questionnaires pertaining to quality of life.

Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd (ages 18 - 85) in hoehn and yahr stages 1 - 3. 2. subjects need to demonstrate a score of equal to or greater than 23 on the mini mental state examination. exclusion criteria: 1. subjects with a history of other neurological diseases (i.e. stroke, multiple sclerosis). 2. subjects with a history of severe cardiopulmonary disease, uncontrolled hypertension, orthostatic hypotension, uncontrolled diabetes, severe osteoporosis. 3. subjects with a history of pd-specific surgical procedure such as deep brain stimulation etc. 4. subjects with a history of head injury. 5. subjects with a history of seizures or epilepsy, 6. subjects who are currently pregnant 7. subjects who use of medications that could alter corticomotor excitability or increase risk of seizure 8. subjects with skull abnormalities, fractures, unexplained, recurring headaches. 9. subjects who have cognitive or communication impairment that would affect participation.

Keywords: aerobic exercise virtual reality
ventilator asynchrony as a predictor of weaning failure

Conditions: Chronic Obstructive Pulmonary Disease(COPD)

Summary: patient ventilator asynchrony is a common problem in mechanically ventilated patients .it is associated with adverse effects including increased work of breathing, patient discomfort, increased need for sedation, prolonged mechanical ventilation , weaning difficulties and weaning failure. 100 mechanically ventilated copd patients were enrolled in this prospective study .detection of patient ventilator asynchrony was done on 30-minute sessions at 12, 24, 36, and 48 hours following intubation by visual assessment of pressure, flow and volume graphs on ventilator .

patient-ventilator asynchrony is defined as a lack of organization between the patient and ventilator timing of both inspiration and expiration . it is a commonly reported problem during mechanical ventilation. thille et al. found that 24% of patients developed asynchrony in at least ten percent of their breaths, moreover they stated that the most frequent asynchronies was each of ineffective triggering and double triggering . eighty percent of chronic obstructive pulmonary disease (copd) patients experienced ineffective triggering, where it is considered the most frequent asynchrony in this group of patients. asynchrony between patient and ventilator also leads to prolonged duration of invasive ventilation, and increase possibility of weaning failure. both spread and intensity of asynchrony during the early phase of weaning in copd patients has never satisfactorily described. the aim of the current study was to describe the patient-ventilator asynchrony and its impact on weaning outcome in mechanically ventilated copd patients.

Eligibility criteria:
inclusion criteria: all copd patients who were diagnosed after history ,physical examination radiology and pulmonary function tests and required mechanical ventilation. exclusion criteria: 1. age \< 18 years 2. tracheostomy 3. failure to trigger breaths even in cases of receiving neuromuscular blocking agents. 4. encephalopathy which is not caused by hypercapnia or hypoxemia either post arrest or due to cerebrovascular stroke 5. patients with unplanned weaning 6. copd patients where intubation not related to exacerbation e.g. acute pulmonary edema. -

Keywords: mechanically ventilated weaning failure copd asynchrony
physical activity levels in covid-19 patients admitted to intensive care

Conditions: COVID-19; Critical Illness; Ards; ICU Acquired Weakness

Summary: this is an observational study exploring the levels of mobility and rehabilitation in patients admitted to critical care with a confirmed diagnosis of covid-19

an admission to an intensive care unit (icu) often results in significant muscle weakness and physical deconditioning, which can take many months or even years for recovery. early and progressive programmes of rehabilitation are recommended to limit any muscle loss and support recovery as early as possible. patients admitted to intensive care with covid-19 have been found to require prolonged periods of mechanical ventilation, high sedation and neuromuscular blocking use and as a result require prolonged stays in the icu. as yet no data exists to examine the specific physical impact this may have, or whether it is safe and feasible to commence this earlier rehabilitation within the icu for patients with a diagnosis of covid-19. our study set out to evaluate the levels of rehabilitation which were delivered in a large acute nhs trust.

Eligibility criteria:
inclusion criteria: * having a confirmed diagnosis of covid-19 * being mechanically ventilated for at least 24 hours * surviving to critical care discharge. exclusion criteria: * none
role of femoral nerve block on prevention of postoperative deep venous thromboembolism

Conditions: Gonarthrosis

Summary: to investigate whether preemptive analgesic of femoral nerve block could prevent deep venous thromboembolism due to inhibiting the excessive release of neutrophil elastase and inflammatory cytokines.

femoral nerve block is an effective analgesic mode in patients after total knee arthroplasty. in recent studies, there has been shown that a large amount of neutrophil elastase release from neutrophils could induce the development of deep venous thromboembolism and femoral nerve block may reduce the incidence of the development of deep venous thromboembolism. in addition, inflammatory cytokines including interleukin-1(il-1), il-6, il-8 and tumor necrosis factor(tnf) were associated with deep venous thromboembolism. thus, the investigators hypothesised that preemptive analgesic of femoral nerve block could prevent deep venous thromboembolism due to inhibiting the excessive release of neutrophil elastase and inflammatory cytokines.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for total knee arthroplasty under general anesthesia exclusion criteria: * asa physical status ⅳ-ⅴ, * psychiatric illness, * chronic opioid consumption, * patient refusal, * coagulopathy, * peripheral neurological injury, * local anesthesia drug allergy, * preoperative existing deep venous thromboembolism.

Keywords: deep venous thromboembolism femoral nerve block total knee arthroplasty
study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis

Conditions: Moderate to Severe Palmoplantar Psoriasis

Summary: purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.


Eligibility criteria:
inclusion criteria: * subjects with chronic, moderate to severe plaque type psoriasis for at least 6 months prior to randomization and significant involvement of the palms and soles at baseline, defined as palmoplantar investigator's global assessment (ppiga) score of ≥ 3 on a 5-point scale, as well as at least one skin plaque at baseline which is not in the palmoplantar area * candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical treatment (including super potent topical corticosteroids) and/or phototherapy and/or previous systemic therapy exclusion criteria: * forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular psoriasis, palmoplantar pustulosis, acrodermatitis of hallopeau, erythrodermic and guttate psoriasis) * drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers, calcium channel inhibitors or lithium) * ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (cs), uv therapy). washout periods do apply. * prior exposure to secukinumab (ain457) or any other biological drug directly targeting il-17 or the il-17 receptor * use of any investigational drugs within 4 weeks prior to study treatment initiation or within a period of 5 half-lives of the investigational treatment, whichever is longer * active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy * history of hypersensitivity to constituents of the study treatment

Keywords: skin condition, itching, psoriasis vulgaris, relapsing remitting psoriasis, immune-med systemic disease, skin lesions, scaly patches, papules, plaques
efficacy and tolerance evaluation of a topical "revitalizing" face day cream

Conditions: Healthy

Summary: aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the "revitalizing" activity of a face cream applied twice a day, morning and evening, for an uninterrupted period of 8 weeks, by healthy female volunteers aged 45-55 years with face ritidosis and women aged 55-65 years not habitual user of antiage-creams. the study foresaw the comparison within subjects of the study product versus placebo (half face method). it was also aim of this study to evaluate products efficacy and cosmetic acceptability by the volunteers and tolerance both by investigator and volunteers.


Eligibility criteria:
inclusion criteria: * female healthy subjects * age 45-55 years * women aged 55-65 years who are not habitual user of antiage-creams * presence of moderate face ritidosis * agreeing to present at each study visit without make-up * accepting to not change their habits regarding food, physical activity, face cleansing and make- up use * accepting not to expose their face to strong uv irradiation (uv session, or sun bathes) during the entire duration of the study * accepting to sign the informed consent form exclusion criteria: * pregnancy * lactation * change in the normal habits regarding foods, physical activity, face cleansing and make-up use during the month preceding the test * sensitivity to the test products or theirs ingredients * subjects whose insufficient adhesion to the study protocol is foreseeable * participation in a similar study actually or during the previous 3 months * change in the normal life habits during the month preceding the inclusion * dermatological disease (dermatitis; presence of cutaneous disease on the tested area, as lesions, scars, malformations; recurrent facial/labial herpes) * clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.) * diabetes * endocrine disease * hepatic disorder * renal disorder * cardiac disorder * pulmonary disease * cancer * neurological or psychological disease * inflammatory/immunosuppressive disease * drug allergy * drugs/cutaneous medical or surgical procedures at level of the tested area during the previous 3 months * anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with except of contraceptive or hormonal treatment starting from at least 1 year); * assumption of drugs able to influence the test results in the investigator opinion

Keywords: skin aging anti-aging cream wrinkles
changes in renal perfusion during hemodialysis in patients with end-stage renal disease

Conditions: End-stage Renal Disease

Summary: residual renal function (rrf) characteristically declines after patients with end-stage renal disease (esrd) initiate dialysis. although rrf preservation correlates with improved patient\&#39;s quality of life and survival prospects, poor understanding of the pathophysiology underlying rrf decline limits protection strategies.

hemodialysis (hd) is the primary renal replacement therapy for patients with end-stage renal disease. however, residual renal function (rrf) characteristically declines after these individuals start dialysis. this loss of rrf not only impacts the adequacy of dialysis and control of complications but also affects the patient\&#39;s quality of life and survival prospects. due to a lack of clear understanding regarding the pathophysiology underlying this decline in rrf, no effective strategies exist for its preservation at present. the objective of this study is to explore the changes in renal perfusion during hemodialysis in patients with end-stage renal disease, and provide a new idea for protection of rrf. this study was an observational study, and no interventions were performed.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * clinical diagnosis of end-stage renal disease requiring long-term hemodialysis treatment, with dialysis duration ≤ 3 months; * urine output \&gt; 500ml/day or gfr \&gt; 3ml/min/1.72m2; * signed and dated informed consented is obtained. exclusion criteria: * presence of vascular access dysfunction (blood flow rate \&lt; 180ml/min); * severe heart failure; * active infection; * infectious disease; * patients with severe anemia; * patients with polycystic kidney disease; * expected dialysis duration \&lt; 6 months; * pregnancy or lactation women; * patients who are participating in other clinical studies, or who have participated in other clinical studies within 3 months prior to enrollment; * unwillingness to be followed up or poor adherence to treatment; * other circumstances that the investigator considers unsuitable for enrolment.

Keywords: hemodialysis renal perfusion end-stage renal disease
phase ib of recombinant human albumin injection

Conditions: Ascites

Summary: a randomized, multicenter,open-label, positive-controlled, multi-dose phase 1 study to evaluate the safety, tolerance,efficacy, pharmacokinetics and immunogenicity of recombinant human albumin injection in patients with hepatic cirrhosis

this study was to evaluate the safety, tolerability,efficacy, pharmacokinetics and immunogenicity of recombinant human albumin injection in patients with hepatic cirrhosis. the study design consists of two phases: screening and treatment phase(dose increasing stage).following the screening phase, all eligible subjects will be randomized to receive recombinant human albumin injection or humanalbumin, study medication in a 3:1 ratio.dose increasing stage (including 3 dose groups with increasing dose, and each group was set with humanalbumin control).the initial dose was 10g. the highest dose group was set at 30g.

Eligibility criteria:
inclusion criteria: 1. 18-75 years of age; 2. no less than 45 kg. 3. diagnosed with ascites due to cirrhosis. exclusion criteria: 1. allergy to biological products; 2. west-haven he ≥ iii ; 3. uncontrolled severe infections; 4. hrs. serum creatinine (cr)\>2×uln, or cr increase\>50% during the screening period; 5. combined with other serious underlying diseases. 6. organ transplant recipients; 7. child-bearing females. pregnancy test positive. refusing to take contraceptive measures; (8) participation in other clinical trials. using study drugs within three month; (9) with the following laboratory test abnormality: 1. plt\<30×109/l, hgb\<70 g/l; 2. alt and (or) ast\> 5×uln, tbil\>3×uln; 3. prothrombin activity \ 5s; 4. lvef \<50%; 5. the 24h urine volume exceeds 1500 ml/day ; 10) other subjects by investigator's opinion.
rapid point-of-care salivary diagnostic for periodontal health

Conditions: Gingivitis; Periodontal Disease

Summary: the purpose of this study is to learn if a chair-side testing device will accurately measure levels of a salivary biomarker and thus indicate if a patient has periodontal health, gingivitis or periodontal disease.

human subjects will participate in this cross-sectional study by attending a single visit where their mouth will be examined and saliva will be collected to help determine the accuracy of a poc salivary diagnostic device. the study population will consist of 174 persons (58 that are orally healthy and have no oral discomfort; 58 that have gingivitis; and 58 that have periodontitis. the device results (i.e., visual and optical scans) will be compared against the luminex results by two methods: 1) the bland-altman procedure and 2) discriminant analysis that examines whether the concentration would correctly identify the subject as health or disease using a defined threshold for mmp-8 levels. three groups of individuals will be recruited: those that are orally healthy and do not have any oral discomfort (n=58), those who have gingivitis (i.e., bleeding gums; n=58), and those who have periodontal disease (n=58). the groups will be matched by gender and smoking status. women are predicted to account for 50% of the participants. the age distribution will be 18 to 95 years. subjects will not be excluded based on race, gender, or ethnicity.

Eligibility criteria:
inclusion criteria: * males or females of all racial and ethnic groups over 18 years of age; * at least 20 erupted teeth and the ability to provide expectorated saliva; * able and willing to comply with study requirements; and * have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures exclusion criteria: * prisoners or institutionalized individuals; * persons with acute illness or infectious disease (as evidenced by fever, malaise, sore throat, recurrent cough, lymphadenopathy, swelling and/or a physician consultation); * evidence of oral mucosal lesion or ulceration; or * use of glucocorticoids or cyclooxygenase inhibitors (i.e. such as ibuprofen, naprosyn(aleve) or non-steroidal anti-inflammatory drug) daily for the past two weeks.

Keywords: bleeding gums gum inflammation saliva
e3810-a001-312: efficacy and safety of 10 mg rabeprazole for treating heartburn in frequent sufferers

Conditions: Heartburn

Summary: the purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.

this is a multicenter, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn. the study will last for up to five weeks and consists of the following three phases: a one to two week screening period that includes a one week, single-blind, placebo run-in phase, a two week double-blind, randomized treatment phase, and a one week single-blind, placebo follow-up phase.

Eligibility criteria:
key inclusion criteria: 1. male or female patients \> 18 years of age. 2. if female, not of childbearing potential by reason of surgery or menopause, or of childbearing potential, but using an approved method of contraception since the last menstrual period. females of childbearing potential must have a negative serum pregnancy test before starting the study. 3. patients must report a history of heartburn at least two days per week over the past month. key exclusion criteria: 1. history of erosive esophagitis verified by endoscopy. 2. history of gastroesophageal reflux disease (gerd) diagnosed by a physician. 3. patients who have a history of barrett's esophagus or esophageal stricture. 4. evidence of any medical condition that may interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study. 5. patients who require continuous use of proton pump inhibitors, histamine receptor (h2) blockers, or prokinetics. prior intermittent use of these agents is permitted if they are discontinued at least three days prior to the run-in phase. the h2 blocker, cimetidine (tagamet®), must be discontinued for at least seven days before the study drug is administered.

Keywords: heartburn rabeprazole
early assessment of anthracycline-induced cardiotoxicity (cardiotox)

Conditions: Lymphoma; Heart Failure, Congestive

Summary: anthracycline-based chemotherapy is a key point of the treatment of patients with hodgkin's and non-hodgkin's lymphomas. however, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure. the standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. the aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and nt-probnp) and structural changes on cardiac mr in predicting anthracycline cardiotoxicity.


Eligibility criteria:
inclusion criteria: * histologically proven lymphoma (hodgkin's or non-hodgkin's) * age \> 18 y/o and \< 70 y/o * who score \< or = 2 * life expectancy \> 6 mo * left ventricular ejection fraction \> 50% * informed consent exclusion criteria: * previous chemotherapy using anthracyclines * history of radiation therapy * history of congestive heart failure * history of chronic renal insufficiency * contra indication to mr examination * atrial fibrillation and significant arrhythmia * pregnancy

Keywords: lymphoma anthracyclines heart failure radionuclide magnetic resonance imaging troponin natriuretic peptide, brain
internet auditory rehabilitation: follow-up to adult hearing screening

Conditions: Hearing Loss

Summary: the purpose of this study is to see if a newly developed program called "i manage my hearing loss" (imanage) will increase the number of individuals who visit an audiologist after failing a hearing screening. the imanage program will educate individuals about hearing loss, demonstrate that hearing problems are important, demonstrate that support from family and friends is important and help participants identify the benefits and concerns related to seeking help for hearing loss.


Eligibility criteria:
inclusion criteria: * subject must fail a hearing screening (any threshold \>34 decibels hearing level at 2000 or 3000 hertz in either ear) or show equivalent or greater degree of hearing loss on most recent audiogram. * free of obvious outer or middle ear disease (as measured by otoscopy) * between the ages of 45 and 85 * pass a health literacy screening * pass a thinking skills screening exclusion criteria: * experience seeing an audiologist for a hearing evaluation or management * experience using a hearing aid

Keywords: hearing screening, auditory rehabilitation
has the covid-19 pandemic affected injury in football?

Conditions: Injuries

Summary: this study aims to compare the injuries that occurred in the football players after the isolation and lack of training caused by new coronavirus disease (covid-19), with the previous season, based on the example of a professional football team in turkey.

this study aims to compare the injuries that occurred in the football players who faced an intense match tempo after the isolation and lack of training caused by covid-19, as well as the stress and uncertainty, with the previous season, based on the example of a professional football team in turkey. injury follow-up data were examined.

Eligibility criteria:
inclusion criteria: * having a musculoskeletal injury during the official match or team training in the 2019-2020 or 2020-2021 season exclusion criteria: * signing a contract with trabzonspor a team in the 2020-2021 season

Keywords: covid-19 football injuries